Email this article Сombined treatment of squamous-cell anal cancer
- Authors: Kim D.F.1, Nikolayev A.V.1, Barsukov Y.A.1, Tkachev S.I.1, Gordeyev S.S.2
-
Affiliations:
- N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
- I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia
- Issue: Vol 1, No 4 (2012)
- Pages: 9-14
- Section: IN FOCUS
- Published: 28.02.2015
- URL: https://onco-surgery.info/jour/article/view/59
- DOI: https://doi.org/10.17650/2220-3478-2012-0-4-9-14
- ID: 59
Cite item
Full Text
Abstract
Since 1974 chemoradiation scheme proposed by Nigro remains the standard of care for squamous-cell anal cancer in most countries. Improvement of treatment results can be achieved by developing new treatment schemes including different radio- and chemosensitizers.
Methods. Results of treatment of 157 T1–4N0–2M0 squamous-cell anal cancer patients, which underwent treatment during 1990–2012 were analyzed. Patients were divided into 3 groups: group A received hyperfractionated radiotherapy (RT) single dose 1.2 Gy bid, total dose 40–44 Gy with 3–5 sessions of local hyperthermia (HT) during treatment; group B had similar RT + HT scheme with addition of chemotherapy (CT) with cisplatin 20 mg/m2 in days 1, 3 weeks 1–4 and bleomycin 15 mg in days 2, 4 weeks 1–4; group C had RT with single dose 2 Gy, same total dose, HT and CT as in group B and additionally received metronidazole 10 g/m2 per rectum in a polymeric composition. Two weeks after 1st treatment stage a second course of RT was carried out 20–24 Gy in 2 Gy fractions in all patient groups.
Results. Sphincter-sparing treatment was carried out in 11 (50 %), 71 (80.68 %) and 44 (93.62 %) in groups A, B and C accordingly. Three year overall survival (OS) was 60.0; 82.4; 96.4 %; 3-year disease-free survival (DFS) 36.6; 69.8 and 76.3 % accordingly.
Conclusions. In our study combined treatment using radiosensitization allow to improve sphincter preservation rate to 93 %, improve OS and DFS for squamous-cell anal cancer patients.
About the authors
D. F. Kim
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Author for correspondence.
Email: kdf1976@rambler.ru
Russian Federation
A. V. Nikolayev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
Yu. A. Barsukov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
S. I. Tkachev
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowRussian Federation
S. S. Gordeyev
I.M. Sechenov First Moscow State Medical University, Ministry of Health of RussiaDepartment of Oncology, Faculty of Therapeutics Russian Federation
References
Supplementary files
